TrialThe Lancet. Haematology2017

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.

Claire N Harrison et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.